J C Oliver

First-in-human phase 1/2a trial of CRLX101, a cyclodextrin-containing polymer-camptothecin nanopharmaceutical in patients with advanced solid tumor malignancies

Glen J. Weiss, Joseph Chao, Jeffrey D. Neidhart et al. · Investigational New Drugs · 2013 · 220 citations · Full text

Pharmacy, Oncology, Pharmacology +14

Cytokine kinetics in an in vitro whole blood model following an endotoxin challenge.

J C Oliver, L A Bland, Carl W. Oettinger et al. · PubMed · 1993 · 142 citations

Life Sciences, Immunology, Pharmacokinetics +15

Phase I/II dose escalation study of angiotensin 1-7 [A(1-7)] administered before and after chemotherapy in patients with newly diagnosed breast cancer

Kathleen E. Rodgers, J C Oliver, Gere S. diZerega · Cancer Chemotherapy and Pharmacology · 2005 · 113 citations

Medicine, Oncology, Pharmacology +12

Normalization of uremic acidosis in hemodialysis patients with a high bicarbonate dialysate.

Carl W. Oettinger, J C Oliver · Journal of the American Society of Nephrology · 1993 · 70 citations · Full text

Medicine, Nephrology, Physiology +17

Pyrogenic reactions in patients receiving conventional, high-efficiency, or high-flux hemodialysis treatments with bicarbonate dialysate containing high concentrations of bacteria and endotoxin.

Steven M. Gordon, Carl W. Oettinger, L A Bland et al. · Journal of the American Society of Nephrology · 1992 · 63 citations · Full text

Medicine, Microbiology, Nephrology +16